Thus, the additive increased inhibitory activity of TKI and statins against CML cells may be mediated through blockade of the c-Myc pathway, which can be considered a potential therapeutic target for eradication of leukemic progenitor cells in CML patients. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.